Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CYTK Cytokinetics Inc
- Stocks
- Healthcare
- NASDAQ: CYTK
Price (delayed)
$31.02
Market cap
$3.7B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.29
Enterprise value
$4.42B
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by
Highlights
Cytokinetics's gross profit has increased by 4% from the previous quarter
The revenue has increased by 4% since the previous quarter
CYTK's equity has dropped by 97% since the previous quarter but it is up by 33% year-on-year
Cytokinetics's quick ratio has decreased by 16% YoY and by 3.1% from the previous quarter
The net income is down by 16% year-on-year and by 4.4% since the previous quarter
Key stats
What are the main financial stats of CYTK
Market
Valuations
Earnings
Shares outstanding
119.43M
Market cap
$3.7B
Enterprise value
$4.42B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
191.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
230.1
Revenue
$19.22M
Gross profit
$19.22M
Operating income
-$565.64M
Net income
-$615.26M
EBIT
-$575.79M
EBITDA
-$566.29M
Free cash flow
-$407.57M
Per share
Balance sheet
Liquidity
EPS
-$5.29
EPS diluted
-$5.29
Free cash flow per share
-$3.44
Book value per share
-$2.25
Revenue per share
$0.16
TBVPS
$10.67
Total assets
$1.26B
Total liabilities
$1.53B
Debt
$791.06M
Equity
-$266.41M
Working capital
$796.33M
Debt to equity
-2.97
Current ratio
5.99
Quick ratio
5.89
Net debt/EBITDA
-1.27
Margins
Efficiency
Dividend
EBITDA margin
-2,946.7%
Gross margin
100%
Net margin
-3,201.5%
Operating margin
-2,943.3%
Return on assets
-43.7%
Return on equity
N/A
Return on invested capital
-29.4%
Return on capital employed
-52.1%
Return on sales
-2,996.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYTK stock price
How has the Cytokinetics stock price performed over time
Intraday
-0.96%
1 week
1.57%
1 month
-27.59%
1 year
-36.85%
YTD
-34.06%
QTD
-22.82%
Financial performance
How have Cytokinetics's revenue and profit performed over time
Revenue
$19.22M
Gross profit
$19.22M
Operating income
-$565.64M
Net income
-$615.26M
Gross margin
100%
Net margin
-3,201.5%
Cytokinetics's operating margin has soared by 78% YoY
The net margin has soared by 77% YoY
The net income is down by 16% year-on-year and by 4.4% since the previous quarter
Cytokinetics's operating income has decreased by 14% YoY and by 5% from the previous quarter
Price vs fundamentals
How does CYTK's price correlate with its fundamentals
Growth
What is Cytokinetics's growth rate over time
Valuation
What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
191.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
230.1
The EPS has grown by 2% YoY
CYTK's equity has dropped by 97% since the previous quarter but it is up by 33% year-on-year
CYTK's P/S is 82% below its last 4 quarters average of 1088.0 and 55% below its 5-year quarterly average of 427.2
The revenue has increased by 4% since the previous quarter
Efficiency
How efficient is Cytokinetics business performance
The ROS has soared by 78% YoY
The company's return on assets rose by 35% YoY and by 4.2% QoQ
CYTK's return on invested capital is up by 21% year-on-year and by 2% since the previous quarter
Dividends
What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYTK.
Financial health
How did Cytokinetics financials performed over time
The total assets is 17% smaller than the total liabilities
The total assets has surged by 56% year-on-year but it has declined by 10% since the previous quarter
Cytokinetics's total liabilities has increased by 27% YoY
CYTK's equity has dropped by 97% since the previous quarter but it is up by 33% year-on-year
Cytokinetics's debt to equity has shrunk by 55% YoY but it has increased by 49% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.